This Solicitation opportunity from Department Of Defense was posted on July 16, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The Department of War, through the Defense Health Agency, is soliciting quotes under RFQ HT9402-26-Q-9304 to establish Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program agreements for newly approved pharmaceutical agents, in compliance with 10 U.S.C. § 1074g and 32 CFR § 199.21. The solicitation targets nine specific drugs scheduled for review by the Pharmacy and Therapeutics Committee in August 2026, including Atoncy for ADHD, Baxfendy for diuretics, Duloxetine for depression, Filkri for white blood cell stimulation, Hepcludex for hepatitis D, Lynavoy for gastrointestinal use, Veppanu for breast cancer, Xocova for COVID-19, and Xtoro for antibiotics. Offerors must submit pricing data for each 11-digit NDC number, with unit prices stated to four decimal places and consistent across all package sizes, alongside clinical and logistical information to support clinical effectiveness and cost-effectiveness evaluations. The selection process is driven by the P&T Committee’s determination of relative clinical benefit and net ingredient cost, directly influencing placement into tiered formulary categories such as Basic Core, Extended Core, or Non-formulary, with Filkri specifically eligible only for the Additional Discount Program due to non-TAA compliance. All submissions must be electronically delivered by July 27, 2026, and require active SAM registration, valid CAGE codes, original or electronic signatures, and compliance with the Quote Review Checklist and fully executed signature pages. Participation necessitates affiliation with the DOW Prime Vendor Program and commitment to establish a limited distribution channel with Accredo for TRICARE mail-order fulfillment. Pricing is not tied to fixed quantities but will be loaded into DLA’s electronic pricing system upon contract execution, with payment processed quarterly and due 70 days after utilization data is provided to manufacturers. Failure to meet payment obligations may result in termination of the UF ADP and reconsideration of formulary status. The government reserves the right to evaluate combination agents and multiple formulations as single entities. Trade Agreement Act compliance is the responsibility of DLA, not the offeror, and contracts may be unilaterally terminated if FSS or Big 4 pricing becomes more advantageous, or if FSS interim agreements expire without successor contracts. Performance is governed by agreements effective upon signature, with place of performance in San Antonio, Texas, and invo
General Info
Agency
NAICS
Place of Performance
TX, 78230, USASet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following August 2026 newly approved drugs will be reviewed:
a. Atoncy – ADHD Agents – Subclass: Non-stimulants
b. Baxfendy – Diuretics – Subclass: Mineralocorticoid Receptor Antagonists
c. Duloxetine - Antidepressants And Non-opioid Pain Syndrome Agents – Subclass: SNRI
d. Filkri – White Blood Cell Stimulants – Subclass: Filgrastims (Only ADP eligible due to non-TAA compliance)
e. Hepcludex – Hepatitis D Agent – Subclass: NA
f. Lynavoy – Gastrointestinal-2 Agents – Subclass: NA
g. Veppanu - Breast Cancer Agents – Subclass: Estrogen Receptor Antagonist
h. Xocova – Antivirals – Subclass: FDA Approved COVID Therapeutics
i. Xtoro - Antibiotics – Subclass: Quinolones
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9304.
Pre-quotation teleconference is on July 15, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POCs in Part 2.3.1., no later than the date stated in Part 2.3.2.
More opportunities from Department Of Defense → Defense Health Agency
Same awarding agency
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 650+ contractors already using CLEATUS
